Patients with hepatitis B are treated with interferon antiviral therapy, and the applied interferon is currently recommended in the Treatment Guidelines to be applied with pegylated interferon, one injection per week for 48 weeks. The probability of conversion with pegylated interferon antiviral therapy is divided into: hepatitis B virus DNA conversion rate and hepatitis B surface antigen conversion rate. The rate of hepatitis B virus DNA reversion is 14% for major third-positive hepatitis B treated with pegylated interferon and 19% for three years after stopping the drug; the rate of surface antigen reversion is 3% and increases to 11% three years after stopping the drug. When pegylated interferon antiviral therapy was applied to hepatitis B minor third-positive, the hepatitis B virus DNA conversion rate increased significantly to 19%, and the surface antigen conversion rate was also 3%; the hepatitis B virus DNA conversion rate was 18% and the surface antigen conversion rate was 8% three years after stopping the drug.